Business Context and Reporting Period
Company: Bovie Medical Corporation (Note: Metadata referenced "Apyx Medical Corp," but the filing text identifies the registrant as Bovie Medical Corporation).
Filing Type: Form 10-Q (Quarterly Report).
Reporting Period: Quarter and six months ended June 30, 2009.
Business Overview: Bovie Medical Corporation manufactures and markets electrosurgical devices, including generators, accessories, saline-enhanced resection devices, and cauteries. Products are sold globally through distributors to hospitals and healthcare facilities. The company operates two reportable segments: Bovie Medical Corporation (USA) and Bovie Canada.
Key Financial Metrics
| Metric | Six Months Ended June 30, 2009 | Six Months Ended June 30, 2008 | Three Months Ended June 30, 2009 | Three Months Ended June 30, 2008 |
|---|---|---|---|---|
| Sales (Revenue) | $14,048,901 | $13,662,879 | $6,831,578 | $6,985,312 |
| Gross Profit | $6,300,956 | $5,486,378 | $2,981,142 | $2,900,453 |
| Gross Margin | 44.8% | 40.2% | 43.6% | 41.5% |
| Net Income | $605,885 | $1,420,664 | $206,672 | $1,230,220 |
| Operating Income | $814,418 | $534,395 | $275,814 | $245,442 |
| Cash from Operations | $390,916 | $707,430 | N/A | N/A |
| Cash and Equivalents (End of Period) | $3,115,098 | $3,778,330 | $3,115,098 | $3,778,330 |
| Total Debt (Current + Long Term) | $5,000,000 | $4,000,000 | $5,000,000 | $4,000,000 |
| Working Capital | $10,041,478 | $9,721,072 | $10,041,478 | $9,721,072 |
Note: Total Debt includes $1,000,000 line of credit, $125,000 current mortgage, and $3,812,500 long-term mortgage. 2008 debt figures exclude the line of credit which was not utilized.
Material Changes vs. Prior Period
- Revenue Growth: Six-month sales increased 2.8% year-over-year, driven by a 6.1% increase in domestic sales (primarily OEM electrosurgical products). International sales declined 10.5%.
- Profitability Decline: Net income for the six months ended June 30, 2009, decreased 58.6% compared to the prior year. This decline is primarily due to the absence of a one-time $1.5 million gain on the cancellation of an agreement with Boston Scientific Corporation recorded in 2008.
- Operating Efficiency: Operating income increased 52.4% year-over-year for the six-month period, reflecting improved gross margins (44.8% vs. 40.2%) and cost management, despite higher professional service fees.
- Expense Increases: Professional services increased 123.5% year-over-year (six months) due to legal costs associated with litigation against Erbe USA, Inc. Research and development expenses increased 6.3% due to new product development (SEER, BOSS, J-Plasma).
- Capital Expenditures: Cash used in investing activities increased significantly to $2.05 million (from $0.64 million in 2008) due to the refurbishment of a new facility purchased in late 2008.
Guidance, Outlook, and Risks
Outlook and Management Commentary
- Product Pipeline: Management is focused on high-margin new products. 510(k) submissions have been filed for the BOSS orthopedic device, Seal-n-Cut vessel sealing instruments, and the ICON VS generator. The J-Plasma technology application is pending FDA action.
- Market Strategy: The company is establishing direct sales teams for new products targeting markets estimated at over $500 million (SEER/BOSS) and $1 billion (vessel sealing).
- Liquidity: Management believes cash on hand ($3.1 million) and operating cash flows are sufficient for at least one year. An additional $4.0 million borrowing capacity remains available under the existing credit facility.
Risks and Contingencies
- Legal Proceedings: A civil action by Erbe USA, Inc. alleges misappropriation of trade secrets by a former employee now working for Bovie. The case is stayed pending discovery; exposure is currently indeterminable.
- Customer Concentration: The ten largest customers accounted for 73% of net revenues in the first six months of 2009. One customer alone accounted for 27% of total sales.
- Economic Conditions: The global recession and credit market constriction may cause hospitals to postpone spending or delay orders.
- Lease Obligations: The company relocated to a new facility but retains a lease in St. Petersburg, Florida. If the space cannot be subleased, the company may face charges for remaining lease rentals.
Investor Verification Checklist
- One-Time Gains: Verify the impact of the $1.5 million non-recurring gain in 2008 on year-over-year net income comparisons.
- Legal Exposure: Monitor the status of the Erbe USA, Inc. lawsuit and potential financial impact on future quarters.
- Customer Concentration: Assess the risk associated with reliance on the top 10 customers (73% of revenue) and the single largest customer (27% of revenue).
- Capital Expenditures: Confirm the timeline for ROI on the $2.05 million spent on facility refurbishment and new product tooling.
- Debt Utilization: Review the utilization of the $1.0 million line of credit and the company's ability to service the $3.9 million mortgage obligation.
- Regulatory Approvals: Track the FDA approval status of the BOSS, Seal-n-Cut, and J-Plasma devices, which are critical to the stated growth strategy.